These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 12753269)
1. Evolution of serum phosphate in long intermittent hemodialysis. Fajardo L; Campistrús N; Ríos P; Gómez T Kidney Int Suppl; 2003 Jun; (85):S66-8. PubMed ID: 12753269 [TBL] [Abstract][Full Text] [Related]
2. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D; J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633 [TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
4. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012. Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS; PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510 [TBL] [Abstract][Full Text] [Related]
5. Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients. Tonelli M; Wang W; Hemmelgarn B; Lloyd A; Manns B; Am J Kidney Dis; 2009 Dec; 54(6):1108-15. PubMed ID: 19619920 [TBL] [Abstract][Full Text] [Related]
6. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis. Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174 [TBL] [Abstract][Full Text] [Related]
7. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism]. Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839 [TBL] [Abstract][Full Text] [Related]
8. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941 [TBL] [Abstract][Full Text] [Related]
9. Phosphorus control in peritoneal dialysis patients. Yavuz A; Ersoy FF; Passadakis PS; Tam P; Evaggelos DM; Katopodis KP; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis GJ; Dombros NA; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis CP; Yavuz M; Tsakiris DJ; Dimitriades AC; Yilmaz ME; Gültekin M; Süleymanlar G; Oreopoulos DG Kidney Int Suppl; 2008 Apr; (108):S152-8. PubMed ID: 18379539 [TBL] [Abstract][Full Text] [Related]
10. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L. Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334 [TBL] [Abstract][Full Text] [Related]
11. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Tzanakis IP; Papadaki AN; Wei M; Kagia S; Spadidakis VV; Kallivretakis NE; Oreopoulos DG Int Urol Nephrol; 2008; 40(1):193-201. PubMed ID: 18193489 [TBL] [Abstract][Full Text] [Related]
12. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430 [TBL] [Abstract][Full Text] [Related]
13. Circadian rhythm of serum phosphate, calcium and parathyroid hormone levels in hemodialysis patients. Micozkadioglu H; Ozelsancak R; Yildiz I; Erken E; Zumrutdal A; Torun D; Haberal M Clin Lab; 2013; 59(1-2):79-84. PubMed ID: 23505910 [TBL] [Abstract][Full Text] [Related]
14. Are we overconcerned about secondary hyperparathyroidism and underestimating the more common secondary hypoparathyroidism in our dialysis patients? Jeloka T; Mali M; Jhamnani A; Konde S; Jadhav V J Assoc Physicians India; 2012 Feb; 60():102-5. PubMed ID: 22715556 [TBL] [Abstract][Full Text] [Related]
15. Extended release nicotinic acid - a novel oral agent for phosphate control. Sampathkumar K; Selvam M; Sooraj YS; Gowthaman S; Ajeshkumar RN Int Urol Nephrol; 2006; 38(1):171-4. PubMed ID: 16502077 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645 [TBL] [Abstract][Full Text] [Related]
17. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. Hervás JG; Prados D; Cerezo S Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270 [TBL] [Abstract][Full Text] [Related]
19. Effect of CAPD and hemodialysis on parathyroid function. Malberti F; Corradi B; Imbasciati E Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912 [TBL] [Abstract][Full Text] [Related]
20. Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Toussaint N; Boddington J; Simmonds R; Waldron C; Somerville C; Agar J Hemodial Int; 2006 Jul; 10(3):280-6. PubMed ID: 16805890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]